AI Drug Creation
Development of ABS-101: A potential best-in-class anti-TL1A antibody for the treatment of inflammatory bowel disease
The application of generative artificial intelligence (generative AI) for the discovery and design of novel biologics holds substantial potential for the biopharmaceutical industry, although practical implementations are still limited. In this poster, we introduce the development of ABS-101, a potential best-in-class antibody targeting TL1A for the treatment of inflammatory bowel disease and other indications with hallmarks of inflammation and fibrosis.
Absci’s Integrated Drug Creation Platform, featuring generative AI models, was leveraged to design antibodies against desired epitopes with the aim of achieving an optimized target product profile, including reduced immunogenicity risk and binding to both monomeric and trimeric forms of TL1A.
